Production of a Soluble Recombinant Antibody Fragment against MMP9 Using

Chang-Hun Yeom, Hee-Jin Jeong

Abstract read

In one paragraph

Article in Medicina (Kaunas, Lithuania), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Chang-Hun YeomDepartment of Biological and Chemical Engineering, Hongik University, Sejong 30016, Korea.

Hee-Jin JeongDepartment of Biological and Chemical Engineering, Hongik University, Sejong 30016, Korea.

Funding

NRF grant funded by the Korean government NRF-2020R1I1A307411712Real National R&D Challenge Program grant funded by the Korea Institute of Human Resources Development in Science & Technology 202101250001WISET grant funded by the Ministry of Science and ICT(MSIT) under the Program for Returners into R&D 2020-24

6 · The paper itself

Abstract

Matrix metalloproteinase 9 (MMP9) is involved in several aspects of the pathology of cancer, including invasion, metastasis, and angiogenesis. In this study, we expressed a recombinant scFv-type anti-MMP9 antibody in soluble form using

Indexed as

Immunoglobulin FragmentsMatrix Metalloproteinase 9Escherichia coliHumansImmunoglobulin Variable RegionRecombinant ProteinsImmunoglobulin FragmentsImmunoglobulin Variable RegionMatrix Metalloproteinase 9MMP9 protein, humanRecombinant ProteinsEscherichia colimatrix metalloproteinaserecombinant antibodysoluble expression

Identifiers

PMID34577904

DOI10.3390/medicina57090981

PMCPMC8468072

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.